Drug Information

Drug General Information
Drug ID
D08DFX
Former ID
DCL001169
Drug Name
Canagliflozin
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Approved [467821], [532651], [532916]
Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 2 [467821], [551060]
Company
Johnson & Johnson
Structure
Download
2D MOL

3D MOL
Formula
C24H25FO5S
InChI
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
InChIKey
XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
CAS Number
CAS 842133-18-0
PubChem Compound ID
24812758
PubChem Substance ID
49811874, 57127075, 125299338, 134358471, 135267033, 136023439, 136340353, 136367529, 136368011, 141631822, 144115779, 144224573, 152159581, 152258221, 160647057, 160695863, 160865968, 162011557, 162169318, 162205127, 164837687, 170500828, 172918748, 174530759, 175266021, 175427146, 178101303, 185964359, 196373210, 198993774, 202567714, 211535181, 223258907, 223471388, 223617458, 223705166, 224378424, 226521104, 248537044, 249737173, 250163176, 252109951, 252215091
SuperDrug ATC ID
A10BX11
Target and Pathway
Target(s) SLGT2 Target Info Modulator [532651], [532916]
Reactome Hexose transport
Na+-dependent glucose transporters
Inositol transporters
WikiPathways NRF2 pathway
Nuclear Receptors Meta-Pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
References
Ref 467821(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4582).
Ref 5326512013 FDA drug approvals. Nat Rev Drug Discov. 2014 Feb;13(2):85-9.
Ref 532916Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism. 2014 Oct;63(10):1296-303.
Ref 551060Clinical pipeline report, company report or official report of Johnson & Johnson (2011).
Ref 5326512013 FDA drug approvals. Nat Rev Drug Discov. 2014 Feb;13(2):85-9.
Ref 532916Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism. 2014 Oct;63(10):1296-303.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.